Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous NY-ESO-1-specific CD8-positive T lymphocytes
- Development stage
- Phase 1
- Lead developer
- Adaptimmune Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous NY-ESO-1-specific CD8-positive T lymphocytes are a form of adoptive cell therapy in which a patient's own (autologous) CD8+ T cells are isolated and engineered or selected to specifically recognize the cancer-testis antigen NY-ESO-1. This antigen is highly immunogenic and expressed in various tumors, including melanoma, synovial sarcoma, ovarian carcinoma, fallopian tube carcinoma, myxoid liposarcoma, and others. The therapy involves expanding these specific cytotoxic T cells ex vivo before reinfusing them into the patient to target and destroy tumor cells expressing NY-ESO-1. The mechanism of action is direct recognition and killing of tumor cells presenting NY-ESO-1 peptides via HLA class I molecules on their surface. This approach has shown clinical responses in early-phase trials for advanced cancers refractory to standard treatments[3][7][10].
- Other names
- autologous NY-ESO-1-specific CD8+ T lymphocytesautologous ny-eso-1-specific cd8-positive t lymphocytes
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on autologous NY-ESO-1-specific CD8-positive T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous NY-ESO-1-specific CD8-positive T lymphocytes.